COUMADIN

Compare COUMADIN  to:
Compare
Compare

Generic Name for COUMADIN

Warfarin sodium 1mg, 2mg, 2½mg, 3mg, 4mg, 5mg, 6mg, 7½mg, 10mg (dye-free); scored tabs.

Legal Classification:

Rx

Pharmacological Class for COUMADIN

Coumarin anticoagulant.

Manufacturer of COUMADIN

Bristol-Myers Squibb

Indications for COUMADIN

Thromboembolic disorders. Thromboembolic complications from atrial fibrillation, cardiac valve replacement. Reduce risk of death, recurrent MIs, and thromboembolic events post-MI.

Adult dose for COUMADIN

Individualize. IV: give as slow bolus dose over 1–2 minutes into a peripheral vein. ≥18yrs: Initially 2–5mg orally or IV daily. Usual maintenance: 2–10mg daily. Variations in CYP2C9 or VKORC1 enzymes, elderly, debilitated: use lower initial dose. Monitor PT; adjust dose and interval according to INR and/or PT (INR preferred). Converting from heparin: see literature.

Children's dosing for COUMADIN

<18yrs: see literature.

Also:

Contraindications for COUMADIN

Hazardous hemorrhagic conditions or treatments. Malignant hypertension. Blood dyscrasias. Unsupervised senile, alcoholic, uncooperative, or psychotic patients. CNS, ophthalmic, or traumatic surgery. Major regional, lumbar block anesthesia, spinal puncture. Inadequate lab facilities. Pregnancy (Cat.X).

Warnings/Precautions for COUMADIN

Monitor PT/INR. Hepatic or renal insufficiency. Infection. Trauma. Diabetes. Hypertension. CHF. Edema. Hyperlipidemia. Thyroid disorders. Collagen vascular disease. Protein C deficiency. Heparin-induced thrombocytopenia. Polycythemia vera. Cancer. Vasculitis. Indwelling catheter. Fever. Discontinue if tissue necrosis or systemic cholesterol microembolization occurs. Gangrene. Diarrhea. Disturbances of intestinal flora. Steatorrhea. Dental procedures. Elderly. Asian. Debilitated. Anticoagulation may persist 2–5 days after discontinuation. Write ℞ using fractions rather than decimals. Nursing mothers.

Interactions for COUMADIN

See literature. Potentiated by plasma protein bound drugs, analgesics, antiarrhythmics, antibiotics, β-blockers, diuretics, proton pump inhibitors, psychostimulants, thyroid drugs, uricosurics, vaccines, fibric acid derivatives, vitamin K deficiency, others. Antagonized by antacids, anxiolytics, antihistamines, antipsychotics, barbiturates, statins, hepatic enzyme inducers, oral contraceptives, diets high in vitamin K, others. Potentiates hypoglycemics, anticonvulsants, others. Caution with drugs that may cause hemorrhage (eg, NSAIDs, aspirin), herbal supplements (eg, ginkgo biloba, ginseng, St. John's wort), alcohol. Cholestatic hepatitis with concomitant ticlopidine.

Adverse Reactions for COUMADIN

Tissue or organ hemorrhage, skin or tissue necrosis, hypersensitivity reactions, systemic cholesterol microembolization, purple toes syndrome, vasculitis, hepatic disorders, fever, dermatitis, urticaria, abdominal pain, asthenia, GI upset, headache, pruritus, alopecia, paresthesias.

How is COUMADIN supplied?

Tabs 1mg, 2mg, 2½mg, 3mg, 4mg, 5mg, 6mg—100, 1000
7½mg, 10mg—100
Inj (5mg vial)—6

Related Disease:

Coagulation disorders

Related Resources

FDA warns of medication errors with nimodipine oral capsules

August 02, 2010

The FDA is reminding healthcare professionals that oral nimodipine capsules should be given only by mouth or through a nasogastric tube and should never be given by intravenous administration.

Generic Lovenox approved for anticoagulation

July 26, 2010

The FDA has granted Sandoz approval of a generic version of Lovenox (enoxaparin sodium injection, from sanofi aventis).

Coumadin 1mg tablet blister packs recalled

July 14, 2010

Bristol-Myers Squibb announced a voluntary recall of several lots of Coumadin (warfarin sodium) 1mg tablet blister packs.

Sagent Pharmaceuticals' heparin sodium injection approved

July 01, 2010

The FDA has approved nine presentations of heparin sodium injection from Sagent Pharmaceuticals.

FDA launches "Bad Ad Program" to detect misleading drug ads

May 11, 2010

The FDA's Division of Drug Marketing, Advertising, and Communications (DDMAC) has launched the Bad Ad Program, designed to educate healthcare providers about their role in ensuring that prescription drug advertising and promotion is truthful, and not misleading.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization.

Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions